Department of Pediatrics, Division of Pediatric Cardiology, Heart Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, MLC 2003, Cincinnati, OH 45229, USA.
Department of Pediatrics, Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, MLC 7018, Cincinnati, OH 45229, USA.
Cardiol Clin. 2019 Nov;37(4):533-544. doi: 10.1016/j.ccl.2019.07.002.
Advances in cancer therapies have significantly improved patient outcomes. However, with improvements in survival, the toxicities associated with cancer therapy have become of paramount importance and oncologists are faced with the challenge of establishing therapeutic efficacy while minimizing toxicity. Cardiovascular disease represents a significant risk to survivors of childhood cancer and is a major cause of morbidity and mortality. This article outlines the current state of knowledge regarding cardiotoxicity in children undergoing cancer therapies, including the impact of specific oncologic therapies, recommendations for cardiovascular screening, the management of established cardiac disease, and the evolving field of pediatric cardio-oncology.
癌症治疗的进展显著改善了患者的预后。然而，随着生存率的提高，癌症治疗相关的毒性作用变得至关重要，肿瘤学家面临着在最小化毒性作用的同时确保治疗效果的挑战。心血管疾病是儿童癌症幸存者面临的重大风险，也是发病率和死亡率的主要原因。本文概述了目前关于接受癌症治疗的儿童患者中心血管毒性的知识现状，包括特定肿瘤治疗的影响、心血管筛查建议、已确诊心脏疾病的治疗以及儿科肿瘤心脏病学的发展领域。
